Item 2.02. Results of Operations and Financial Condition.
On November 8, 2018, Histogenics Corporation (Histogenics) issued a press release and is holding a conference call regarding its results of
operations and financial condition for the quarter ended September 30, 2018. The press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
Various statements to be made during the conference call are forward-looking statements under the securities laws. Words such as, but not limited
to, anticipate, believe, can, could, expect, estimate, design, goal, intend, may, might, objective,
plan, predict, project, target, likely, should, will, and would, or the negative of these terms and similar expressions or words, identify
forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Important factors that could cause actual results to differ materially from those reflected in Histogenics forward-looking statements include, among
others: expectations regarding the timing and success of ongoing discussions with the FDA regarding the potential submission of a BLA for NeoCart; Histogenics potential as a treatment for knee cartilage damage; the timing, associated expenses
and ability to obtain and maintain regulatory approval of NeoCart or any product candidates, and the labeling for any approved products; the market size and potential patient population in markets where Histogenics and its partners expect to
compete; updated or refined data based on Histogenics continuing review and quality control analysis of clinical data; the scope, progress, timing, expansion, and costs of developing and commercializing Histogenics product candidates;
the ability to obtain and maintain regulatory approval regarding the comparability of critical NeoCart raw materials following its technology transfer and manufacturing location transition; Histogenics expectations regarding its expenses and
revenue; Histogenics ability to obtain additional debt or equity capital; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of
Operations sections of Histogenics Annual Report on Form
10-K
for the year ended December 31, 2017 and Quarterly Report on Form
10-Q
for the quarter
ended June 30, 2018, which are on file with the Securities and Exchange Commission (SEC) and available on the SECs website at www.sec.gov. Additional factors may be set forth in those sections of Histogenics Quarterly
Report on Form
10-Q
for the quarter ended September 30, 2018, to be filed with the SEC in the fourth quarter of 2018. In addition to the risks described above and in Histogenics Annual Report on
Form
10-K
and Quarterly Reports on
Form 10-Q,
Current Reports on Form
8-K
and other filings with the SEC, other unknown or
unpredictable factors also could affect Histogenics results. Histogenics has not yet received the official FDA meeting minutes from the Type C meeting held on October 30, 2018 and the information in the release and stated on the
conference call may be altered or supplemented by the information contained in the official meeting minutes or any subsequent meetings that may be held with the FDA.
There can be no assurance that the actual results or developments anticipated by Histogenics will be realized or, even if substantially realized, that they
will have the expected consequences to, or effects on, Histogenics. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Histogenics or any person acting on its behalf are expressly qualified in their entirety by
the cautionary statements contained or referred to herein. Histogenics cautions investors not to rely too heavily on the forward-looking statements Histogenics makes or that are made on its behalf. The information conveyed on the conference call
will be provided only as of the date of the call, and Histogenics undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the call after the date thereof, whether as
a result of new information, future events or otherwise.
The information in Item 2.02 of this Current Report on
Form 8-K
and the Exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a
filing.